Table 3:

Univariate analysis of risk of the incidence and persistence of pelvic floor symptoms and support by oxytocin exposure

Pelvic Floor Symptom Domains and Support	Incidence among women exposed to oxytocin	Incidence among women not exposed to oxytocin	Oxytocin exposure and risk of incident symptoms/sign: RR (95% CI)	Persistence among women exposed to oxytocin	Persistence among women not exposed to oxytocin	Oxytocin exposure and risk of persistent symptoms/sign: RR (95% CI)
Pelvic organ prolapse	18/281 (6.4%)	19/341 (5.6%)	1.15 (0.62, 2.15)	1/23 (4.4%)	4/18 (22.2%)	0.20 (0.02, 1.60)
Stress urinary incontinence	27/113 (23.9%)	34/133 (25.6%)	0.93 (0.60, 1.45)	114/192 (59.4%)	124/230 (53.9%)	1.10 (0.93, 1.30)
Urgency urinary incontinence	49/269 (18.2%)	46/328 (14.0%)	1.30 (0.90, 1.88)	20/36 (55.6%)	11/33 (33.3%)	1.67 (0.95, 2.93)
Pain/voiding dysfunction	30/195 (15.3%)	44/237 (18.6%)	0.83 (0.54, 1.27)	29/110 (26.4%)	38/126 (30.2%)	0.87 (0.58, 1.32)
Anal incontinence	33/219 (15.1%)	37/274 (13.5%)	1.12 (0.72, 1.72)	41/86 (47.7%)	38/88 (43.2%)	1.10 (0.80, 1.53)
Defecating dysfunction	38/150 (25.3%)	50/182 (27.5%)	0.92 (0.64, 1.32)	87/155 (56.1%)	106/181 (58.6%)	0.96 (0.80, 1.15)
Maximal vaginal descent ≥ 0 cm	35/300 (11.7%)	60/364 (16.5%)	0.71 (0.48, 1.04)	5/10 (50%)	3/12 (25.0%)	2.00 (0.63, 6.38)

Incidence = Symptom present postpartum/ Symptom absent in third trimester

Persistence =Symptom present postpartum/Symptom present in third trimester